A systematic review and meta-analysis released in October 2024 by JAMA Network of 27 clinical trials (50,496 participants) compared inhaled asthma relievers. Findings show that combining inhaled corticosteroids (ICS) with short-acting β agonists (SABA) or formoterol significantly reduces severe asthma exacerbations and improves asthma control compared to SABA alone. ICS-formoterol showed the greatest benefit, reducing severe exacerbations by 10.3% without increasing adverse events. These results highlight the advantages of ICS-based combination therapies for better asthma management.
Read the full article here.